Quote
71.05
-10.39 (-12.76%)
We have scored 29 news catalysts on GMED (GMED) over the past 12 months. Coverage across the window leans positive (average ticker sentiment +0.82). Most of the impact sits in sector healthcare and forward growth expectations.
Market cap
—
P/E
—
EPS
—
Beta
—
52W range
—
Day range
70.48–75.63
Open
74.10
Prev close
81.44
Volume
9.3M
Avg volume
—
Dividend
—
IPO
—
No scored news tagged GMED or its network in the window yet.
Show more GMED articles →Analysts publish price targets on GMED, and they disagree. Where the share price actually sits among them shows which of their arguments the market is buying — and which it is ignoring.
6 analyst price targets from $80 to $115
as of 2026-09-10
The market is 23% below the median target — more cautious than the analysts.
The reconstruction
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about GMED — not a sector bucket. Click an edge to see the articles that established the link.
Suppliers, customers, partners and competitors of GMED, taken from what the news actually said about them rather than from a sector bucket. The count is how many articles established each link.
Latest scored catalyst for GMED: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
The price sits at the very bottom of the published model range, rejecting all four bull cases to trade 23% below the median target, which shows the market firmly assumes the recent 16.7% growth will collapse toward a 3% pace.
What the disagreement turns on
Does the 10% U.S. spine market-share gain represent a durable structural shift that keeps overall revenue growth in the mid-teens, and the available unit volume data can actually measure this.
The price pays for
It declines to pay for
Written by a language model from the published models, the reported segments and a reverse-DCF — not a recommendation, and not a house view.
Claim by claim
Computed at $74.52 on 2026-09-10 — 58 days ago.
